Psoriasis Drug Linked to Brain Infection
Feb
20
Written by:
2/20/2009
The Food and Drug Administration is investigating a possible link between the psoriasis drug efalizumab, (Raptiva), and three, or possibly four, deaths from a rare degenerative condition of the brain, progressive multifocal leukoencephalopathy, reports the Los Angeles Times health blog.
The illness is characterized by mental deterioration, vision loss and other neurological symptoms, and most often affects people with impaired immune systems.